Skip to content

4D Molecular Therapeutics FDMT Change in Other Assets

Change in Other Assets at other companies

Eli Lilly logo
Eli LillyLLY
$1.65B+98.4%
EyePoint, Inc.
 logo
EyePoint, Inc. EYPT
$3.36M+7,534%
Regenxbio logo
RegenxbioRGNX
$900K+189%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
-$1.28M
PVL
Palvella TherapeuticsPVLA
$357K+144%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$14.55M-3.5%

Other financials

Income statement

See full
Revenue$3.0M+21,664%
Operating income-$73.6M-37.3%
Net income-$68.8M-43.3%
EPS (diluted)-$1.01-17.4%

Balance sheet

See full
Cash & equivalents$72.5M-45.7%
Total debt$20.5M-13.9%
Total equity$451.8M-3.8%
Total assets$512.9M-0.5%

Cash flow

See full
Operating cash flow-$68.1M-42.6%
CapEx--100%
Free cash flow-$68.1M-40.8%

Valuation

See full
Market cap$602.22M+215%
Enterprise value$550.27M+574%
P/S6.8×-8,306×

Profitability

See full
Operating margin-220.1%-110pp
Net margin-174,314.2%-62,763pp
FCF margin-154,209.2%-53,057pp

Returns & leverage

See full
Return on equity-45.4%+29.8pp
Debt / equity0.0×
Current ratio9.3×-3.0×

Where this comes from

Reported directly by 4D Molecular Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentAssets.

The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about 4D Molecular Therapeutics's change in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is 4D Molecular Therapeutics's change in other assets?
4D Molecular Therapeutics (FDMT) reported change in other assets of $670K in Q1 2026.
How has 4D Molecular Therapeutics's change in other assets changed year-over-year?
4D Molecular Therapeutics's change in other assets decreased by 75.9% year-over-year, from $2.78M to $670K.
What does change in other assets mean?
Change in miscellaneous assets affecting operating cash flow.